To the Editor We read with interest the article published by He et al1 focusing on sorafenib with hepatic arterial infusion of chemotherapy (HAIC). He et al1 conducted an open-label phase 3 randomized clinical trial with HAIC using leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) in addition to sorafenib vs sorafenib alone in patients with hepatocellular carcinoma (HCC) and a portal vein tumor thrombosis. The study met its primary end point, median overall survival, and identified an interesting overall response rate (ORR) in this situation (40.8%).